EP Patent

EP2510928A1 — Aclidinium for use in improving the quality of sleep in respiratory patients

Assigned to Almirall SA · Expires 2012-10-17 · 14y expired

What this patent protects

The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.

USPTO Abstract

The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.

Drugs covered by this patent

Patent Metadata

Patent number
EP2510928A1
Jurisdiction
EP
Classification
—
Expires
2012-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Almirall SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.